Research programme: natural killer cell cancer therapies - NantKwest

Drug Profile

Research programme: natural killer cell cancer therapies - NantKwest

Alternative Names: CD19 target activated natural killer cellular therapy - NantKwest; CD19.taNK therapy - NantKwest; CS1 target activated natural killer cellular therapy- NantKwest; CS1.taNK therapy - NantKwest; CST 102; CST 103; haNK cells; HER2.tank; High-affinity natural killer cells; taNK cells; Target-activated natural killer cells; ZRx 102; ZRx 103; ZRx 104

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator ZelleRx
  • Developer NantKwest
  • Class Cell therapies
  • Mechanism of Action Cell death stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Colorectal cancer; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 04 Apr 2017 NantKwest and Viracta Therapeutics enter into a collaboration agreement to investigate combination of natural killer cells and VRx 3996 in broad range of cancers
  • 04 Apr 2017 NantKwest plans clinical trials for haNK and taNK NK cell therapy in combination with VRx 3996
  • 23 Jan 2017 The US FDA approves IND application for haNK cell therapy in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top